From RXMD Filings
Revenue of $5.1 million, an increase of 15% or $656,000 from Q2 2016
Total prescriptions dispensed of 108,000 for the six months ended June 30, 2017, an increase of 5%
Gross margin of 28% for the six month period versus 25% for the same period in 2016
RXMD Comparison... Year 2017 Versus 2016 Month, Quarterly
1/2016 1.3... 1/2017 1.6
2/2016 1.1... 2/2017 1.5
3/2016 1.5... 3/2017 1.6
Total 3.9...2016... 4.7... 2017
4/2016 1.4... 4/2017 1.4
5/2016 1.4... 5/2017 1.9
6/2016 1.7... 6/2017 1.7
Total 4.5...2016... 5.0...2017
7/2016 1.5.... 7/2017 1.7
8/2016 1.75... 8/2017 1.8
9/2016 1.6....
10/2016 1.6
11/2016 1.7
12/2016 1.7
The Problem: FAILURE by a CEO in PENNYLAND, is not only an Acceptable Practice, it REWARDS a CEO... It's much EASIER for CEO to make money selling Company shares, than Build a Company.